Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free BACK Stock Alerts

IMAC (BACK) Competitors

IMAC logo
$0.0002 0.00 (0.00%)
As of 07/24/2026 12:51 PM Eastern
Compare

BACK vs. BTTX, UPHL, ACONW, DHACW, and LFMDP

Should you buy IMAC stock or one of its competitors? MarketBeat compares IMAC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IMAC include Better Therapeutics (BTTX), UpHealth (UPHL), Aclarion (ACONW), Digital Health Acquisition (DHACW), and LifeMD (LFMDP). These companies are all part of the "healthcare" industry.

How does IMAC compare to Better Therapeutics?

Better Therapeutics (NASDAQ:BTTX) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, IMAC had 2 more articles in the media than Better Therapeutics. MarketBeat recorded 2 mentions for IMAC and 0 mentions for Better Therapeutics. IMAC's average media sentiment score of 0.76 beat Better Therapeutics' score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company Overall Sentiment
Better Therapeutics Neutral
IMAC Positive

Better Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, IMAC has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

IMAC has higher revenue and earnings than Better Therapeutics. IMAC is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A
IMAC$72.05K0.01-$9.42M-$3.12N/A

34.0% of Better Therapeutics shares are held by institutional investors. Comparatively, 5.8% of IMAC shares are held by institutional investors. 51.4% of Better Therapeutics shares are held by company insiders. Comparatively, 12.3% of IMAC shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
IMAC N/A N/A -325.44%

Summary

IMAC beats Better Therapeutics on 6 of the 10 factors compared between the two stocks.

How does IMAC compare to UpHealth?

UpHealth (NYSE:UPHL) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

In the previous week, IMAC had 2 more articles in the media than UpHealth. MarketBeat recorded 2 mentions for IMAC and 0 mentions for UpHealth. IMAC's average media sentiment score of 0.76 beat UpHealth's score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company Overall Sentiment
UpHealth Neutral
IMAC Positive

Company Net Margins Return on Equity Return on Assets
UpHealthN/A N/A N/A
IMAC N/A N/A -325.44%

UpHealth has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, IMAC has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

IMAC has lower revenue, but higher earnings than UpHealth. IMAC is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UpHealth$130M0.00-$56.42M$1.980.00
IMAC$72.05K0.01-$9.42M-$3.12N/A

56.1% of UpHealth shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 34.2% of UpHealth shares are owned by insiders. Comparatively, 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

IMAC beats UpHealth on 6 of the 11 factors compared between the two stocks.

How does IMAC compare to Aclarion?

IMAC (NASDAQ:BACK) and Aclarion (NASDAQ:ACONW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

In the previous week, IMAC and IMAC both had 2 articles in the media. Aclarion's average media sentiment score of 1.44 beat IMAC's score of 0.76 indicating that Aclarion is being referred to more favorably in the news media.

Company Overall Sentiment
IMAC Positive
Aclarion Positive

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aclarion has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K0.01-$9.42M-$3.12N/A
Aclarion$77.88KN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
Aclarion N/A N/A N/A

Summary

Aclarion beats IMAC on 3 of the 5 factors compared between the two stocks.

How does IMAC compare to Digital Health Acquisition?

Digital Health Acquisition (NASDAQ:DHACW) and IMAC (NASDAQ:BACK) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

In the previous week, IMAC had 2 more articles in the media than Digital Health Acquisition. MarketBeat recorded 2 mentions for IMAC and 0 mentions for Digital Health Acquisition. IMAC's average media sentiment score of 0.76 beat Digital Health Acquisition's score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company Overall Sentiment
Digital Health Acquisition Neutral
IMAC Positive

Digital Health Acquisition has higher earnings, but lower revenue than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Digital Health AcquisitionN/AN/AN/AN/AN/A
IMAC$72.05K0.01-$9.42M-$3.12N/A

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Digital Health AcquisitionN/A N/A N/A
IMAC N/A N/A -325.44%

Summary

IMAC beats Digital Health Acquisition on 5 of the 6 factors compared between the two stocks.

How does IMAC compare to LifeMD?

LifeMD (NASDAQ:LFMDP) and IMAC (NASDAQ:BACK) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

LifeMD has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LifeMD$193.33MN/AN/AN/AN/A
IMAC$72.05K0.01-$9.42M-$3.12N/A

Company Net Margins Return on Equity Return on Assets
LifeMDN/A N/A N/A
IMAC N/A N/A -325.44%

In the previous week, LifeMD and LifeMD both had 2 articles in the media. LifeMD's average media sentiment score of 1.43 beat IMAC's score of 0.76 indicating that LifeMD is being referred to more favorably in the media.

Company Overall Sentiment
LifeMD Positive
IMAC Positive

5.8% of IMAC shares are held by institutional investors. 12.3% of IMAC shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

LifeMD beats IMAC on 3 of the 5 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BACK vs. The Competition

Export
MetricIMACSpecialty outpatient clinics IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$1K$6.87B$12.26B
Dividend YieldN/AN/A2.67%9.79%
P/E Ratio0.00N/A27.1123.64
Price / Sales0.010.01496.7876.82
Price / CashN/AN/A50.5459.64
Price / Book0.00N/A10.286.07
Net Income-$9.42M-$9.42M$3.60B$331.99M
7 Day PerformanceN/AN/A-1.27%-0.63%
1 Month PerformanceN/AN/A-0.37%-2.00%
1 Year PerformanceN/AN/A18.30%13.62%

IMAC Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BACK
IMAC
N/A$0.00
flat		N/A-99.7%$1K$72.05KN/A180
BTTX
Better Therapeutics
N/A$0.00
flat		N/AN/A$4KN/AN/A40
UPHL
UpHealth
N/A$0.00
flat		N/A+50.0%$2K$130MN/A1,750
ACONW
Aclarion
N/A$0.02
-5.8%		N/A-24.8%$0.00$77.88KN/A7
DHACW
Digital Health Acquisition
N/A$0.02
flat		N/A-61.3%$0.00N/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BACK) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel